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Abstract
Caveolin-3 (Cav-3) is an 18 kDa protein that has been implicated in t-tubule formation
and function in cardiac ventricular myocytes. During cardiac hypertrophy and failure, Cav-3
expression decreases, t-tubule structure is disrupted and excitation–contraction coupling (ECC)
is impaired. Previous work has suggested that Cav-3 overexpression (OE) is cardio-protective,
but the effect of Cav-3 OE on these cellular changes is unknown. We therefore investigated
whether Cav-3 OE in mice is protective against the cellular effects of pressure overload induced
by 8 weeks’ transverse aortic constriction (TAC). Cav-3 OE mice developed cardiac dilatation,
decreased stroke volume and ejection fraction, and hypertrophy and pulmonary congestion in
response to TAC. These changeswere accompanied by cellular hypertrophy, a decrease in t-tubule
regularity and density, and impaired local Ca2+ release at the t-tubules. However, the extent of
cardiac and cellular hypertrophy was reduced in Cav-3 OE compared to WT mice, and t-tubular
Ca2+ current (ICa) densitywasmaintained. These data suggest thatCav-3OEhelps prevent hyper-
trophy and loss of t-tubular ICa following TAC, but that other factors disrupt local Ca
2+ release.
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1 INTRODUCTION
Excitation–contraction coupling (ECC) in cardiac myocytes is initiated
by the action potential, which activates sarcolemmal L-type Ca2+
channels (LTCCs). The consequent Ca2+ influx (ICa) triggers Ca
2+
release from adjacent sarcoplasmic reticulum (SR) via Ca2+ release
channels (ryanodine receptors; RyRs). This Ca2+-induced Ca2+ release
(Fabiato, 1985) produces local increases of cytosolic [Ca2+] (‘Ca2+
sparks’; Cheng, Lederer, & Cannell, 1993) that summate to form the
cytosolic Ca2+ transient, leading to contraction. In ventricular myo-
cytes, ICa, and thusRyR activation, occurs predominantly at specialized
invaginations of the sarcolemma called t-tubules (Cannell, Cheng,
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& Lederer, 1994; Kawai, Hussain, & Orchard, 1999; Lindner, 1957).
This arrangement achieves near-synchronous Ca2+ release (Cheng,
Cannell, & Lederer, 1994), and thus contraction, throughout the cell.
Relaxation occurs as cytosolic [Ca2+] decreases, mainly due to re-
uptake into the SR, but also by removal from the cell via Na+–Ca2+
exchange (Negretti, O'Neill, & Eisner, 1993).
Caveolin-3 (Cav-3) is a cholesterol-binding protein that has been
implicated in the genesis of t-tubules (Parton, Way, Zorzi, & Stang,
1997) and in the localization of LTCC regulatory proteins and ICa to
the t-tubules (Balijepalli, Foell, Hall, Hell, & Kamp, 2006; Bryant et al.,
2014). Cav-3 knock-out (KO) leads to cellular hypertrophy, t-tubule
disorganization and decreased t-tubular ICa density (Bryant et al.,
654 wileyonlinelibrary.com/journal/eph Experimental Physiology. 2019;104:654–666.
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2018b). Disruption of Cav-3 signalling with C3SD peptide (Couet, Li,
Okamoto, Ikezu, & Lisanti, 1997; Feron et al., 1998) also decreases
t-tubular ICa (Bryant et al., 2014), which impairs local SR Ca
2+ release
(Bryant et al., 2014; Bryant et al., 2018a). Interestingly, cardiac hyper-
trophy and heart failure (HF) are associated with decreased Cav-
3 expression (Bryant et al., 2018a), and myocytes from such hearts
also show hypertrophy, t-tubular disruption, decreased t-tubular ICa
density and impaired SR Ca2+ release (Bryant et al., 2015; Bryant
et al., 2018a), suggesting that reduced Cav-3 expression may play
a role in the phenotypic changes observed in these conditions. In
support of this idea, Cav-3 KO results in a progressive cardiomyopathy
characterized by ventricular hypertrophy and dilatation and reduced
fractional shortening (Woodman et al., 2002), while a loss-of-function
mutation in Cav-3, T63S, has been associated with inherited hyper-
trophic cardiomyopathy (Hayashi et al., 2004). In addition, over-
expression (OE) of Cav-3 reduces the functional and phenotypic
changes caused by pressure overload induced by transverse aortic
constriction (TAC; Horikawa et al., 2011; Markandeya et al., 2015),
which normally results in cardiac hypertrophy and failure. However,
the cellular changes underlying this cardioprotection remain unclear.
The present study was undertaken, therefore, to investigate how Cav-
3 OE alters the response of ventricular myocyte structure and ECC to
TAC inmice.
2 METHODS
2.1 Ethical approval
All animal procedureswereapprovedby theAnimalWelfare andEthics
Review Board of the University of Bristol (14/6/2016) and conducted
in accordance with UK legislation (Animals (Scientific Procedures) Act
1986AmendmentRegulations2012 incorporatingEuropeanDirective
2010/63/EU); the study also complieswith the ethical principles under
which Experimental Physiology operates.
2.2 Animals and surgical procedures
Adult (12 week) male homozygous cardiac-specific Cav-3 OE mice,
produced as described previously (Tsutsumi et al., 2008), were used.
Data from these mice, bred at the University of Bristol, are compared
with data obtained from wild-type (WT) littermates that had under-
gone either sham operation or TAC that resulted in HF. The WT data
havebeenpublishedpreviously (Bryant et al., 2018a) so that onlymean
data, rather than original records, are shown for the WT group, for
comparison with the OE data. However, the surgical and experimental
procedures were the same, and performed contemporaneously, for
the WT and Cav-3 OE groups, and data were obtained using the
same techniques and protocols in each group, as described below.
Surgery was performed at 12 weeks of age and myocyte isolations at
20weeks of age.Micewere kept in a temperature-controlled, enriched
environment with ad libitum access to food andwater.
Eight weeks of TAC was used to produce pressure overload, since
this has previously been shown to result in cardiac hypertrophy and
NewFindings
• What is the central question of this study?
What is the cellular basis of the protection conferred
on the heart by overexpression of caveolin-3 (Cav-3 OE)
against many of the features of heart failure normally
observed in vivo?
• What is themain finding and its importance?
Cav-3 overexpression has little effect in normal
ventricular myocytes but reduces cellular hypertrophy
and preserves t-tubular ICa, but not local t-tubular Ca
2+
release, in heart failure induced by pressure overload in
mice. Thus Cav-3 overexpression provides specific but
limited protection following induction of heart failure,
although other factors disrupt Ca2+ release.
failure (Bryant et al., 2018a; Rockman et al., 1991; Tachibana, Naga
Prasad, Lefkowitz, Koch, & Rockman, 2005). Briefly, animals were
anaesthetized with ketamine (75 mg kg−1 I.P., Zoetis UK Limited,
London, UK) and medetomidine (1 mg kg−1 I.P., Orion Corp., FI-02200
Espoo, Finland) and given buprenorphine (0.05 mg kg−1 S.C., Reckitt
Benckiser Health Care (UK) Ltd, Hull, UK) for pain relief; the surgical
plane of anaesthesia was monitored using the limb withdrawal reflex.
The aortic archwas exposed via amedial sternal thoracotomyanda silk
ligature (6-0) placed between the innominate and left carotid arteries
and tied round a 27G needle (0.4 mm OD). Sham animals underwent
the same operation but without placement of the banding suture.
Animals weremaintained post-operatively for 8 weeks before use.
2.3 Echocardiography
In vivo cardiac structure and function were monitored using
echocardiography. Animals were anaesthetized (isoflurane 1–3%,
Merial Animal Health Ltd, Harlow, UK), heart rate was monitored, and
measurements of contractile performancemade fromM-mode images
acquired from the parasternal short axis view using a Vevo 3100
(Fujifilm VisualSonics Inc., Toronto, Ontario, Canada) and MX550D
transducer.
2.4 Myocyte isolation and detubulation
Animals were killed by cervical dislocation and ventricular myocytes
isolated using standard enzymatic digestion via Langendorff perfusion
as described previously (Bryant et al., 2014) and used on the day of
isolation. Detubulation (DT), the physical and functional uncoupling
of the t-tubules from the surface membrane, was achieved using
formamide-induced osmotic shock as described previously (Brette &
Orchard, 2003; Brette, Komukai, &Orchard, 2002; Kawai et al., 1999);
comparison of membrane capacitance and currents in intact and
detubulated myocytes enables the distribution of membrane currents
and current density between the t-tubule and surface membranes to
be determined.
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2.5 Imaging and analysis of t-tubule structure
Cell width and length were measured from brightfield images of iso-
latedmyocytes used for electrophysiology. Cell volumewas calculated
from these measurements as described previously (Boyett, Frampton,
& Kirby, 1991).
Surface and t-tubular cell membranes were labelled by incubating
cells with 5 𝜇mol l−1 di-8-ANEPPS for 10 min. Image volumes were
obtained using an LSM 880 confocal microscope (Zeiss, Carl Zeiss
AG, Oberkochen, Germany) in Airyscan ‘super-resolution’ mode, with
a 1.2 NA, ×40 water immersion objective, sampled at 40 nm in-plane
and 180 nm along the optical axis. Airyscan uses a 32-channel photo-
multiplier tube detector that collects a pinhole-plane image at every
scan position, thus improving spatial resolution. In super-resolution
mode, linear deconvolution provides further improvement to achieve
spatial resolution that is 1.7× that of a conventional confocal micro-
scope. The regularity of t-tubule staining was quantified by applying
a two-dimensional (2D) fast Fourier transform (FFT) to an offset-
subtracted square region of the cell interior, and the power of the first
harmonic normalized to that of the average image intensity (P1/P0). T-
tubule density was calculated from an intracellular volume marked by
hand. The 3D skeleton of the t-tubules was obtained by processing the
volumetric datawith a tubule-enhancing 3D filter, segmenting using an
Otsu threshold in MATLAB R2015a (The Mathworks Inc., Natick, MA,
USA), and converting to a skeletonusing Skeletonize (2D/3D) in ImageJ
(v1.50, NIH, Bethesda, MD, USA). The skeleton was used to calculate
t-tubule density (skeleton length divided by the marked intracellular
volume, 𝜇m 𝜇m−3) and local Eigenvectors for t-tubule angles. Tubule
orientation is expressed relative to the transverse plane, so that 0◦
corresponds to a transverse tubule, while 90◦ corresponds to a tubule
that extends along the cell (i.e. an ‘axial’ tubule).
2.6 Western blotting
Following myocyte isolation, aliquots were pelleted by centrifugation,
the supernatant removed and the cell pellet snap frozen in liquid
nitrogen and stored at−80◦C.Once all samples had been acquired, the
pellets were processed simultaneously by thawing directly into lysis
buffer containing 50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% (v/v) Triton X-100, 1% (w/v) sodium deoxycholate, 0.1% (v/v) SDS,
1 mM phenylmethylsulfonyl fluoride, complete protease inhibitors,
8 𝜇g ml−1 calpain inhibitor I, 8 𝜇g ml−1 calpain inhibitor II, 50 mM
sodium fluoride, 1 mM sodium orthovanadate, and 16 mM sodium
pyrophosphate, homogenized by pipetting and incubated on ice for 15
min. After centrifugation at 13,000 g 4◦C for 15 min the supernatants
were collected, protein concentrations estimated using the Pierce
BCA protein assay (Thermo Fisher Scientific, Waltham, MA, USA) and
adjustments made to allow for equal protein loading on SDS-PAGE.
Ten-microgram samples of the myocyte lysates were run on 4–15%
gradient SDS-PAGEgels and transferredonto Immobilon-Pmembrane.
Blots were probed with antibodies against Cav-3 (BD Biosciences,
San Jose, CA, USA, cat. no. 610420, dilution 1:5000), junctophilin-
2 (JPH-2; Thermo Fisher Scientific, Waltham, MA, USA, cat. no. 40–
5300, dilution 1:500) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Sigma-Aldrich, St Louis, MO, USA, cat. no. G9545, dilution
1:100,000). Protein bands were visualized and images captured using
horseradish peroxidase-conjugated secondary antibodies (Promega,
Madison,WI,USA; cat. no.W4011, 𝛼-rabbitHRP, dilution 1:10,000 and
cat. no. W4021, 𝛼-mouse HRP, dilution 1:10,000), chemiluminescence
and a G:BOX Chemi XT4 imaging system (Syngene, Cambridge, UK).
Gels were first probed with the antibody to Cav-3 or JPH-2, then
stripped using a commercial stripping solution (RestoreTM western
blot stripping buffer, Thermo Fisher Scientific) and re-probed with the
loading control antibody to GAPDH, before being stripped and re-
probed for JPH-2 or Cav-3. The density of the bands was measured
using ImageJ and normalized to GAPDH.
2.7 ICa recording
Myocytes were placed in a chamber mounted on a Nikon Diaphot
inverted microscope. Membrane currents and cell capacitance were
recorded using the whole-cell patch-clamp technique, using an
Axopatch 200B, Digidata 1322A A/D converter and pClamp 10
(Molecular Devices, LLC, San Jose, CA, USA). Pipette resistance was
typically 1.5–3 MΩ when filled with pipette solution (see below), and
pipette capacitance and series resistance were compensated by∼70%
to optimize the measurement of membrane current. Currents were
activated from a holding potential of −80 mV by step depolarization
to −40 mV for 200 ms (to inactivate the sodium current) followed
by steps to potentials between −50 and +80 mV for 500 ms, before
repolarization to the holding potential, at a frequency of 0.2 Hz.
Absolute ICa amplitude (pA) in intact myocytes was measured as
the difference between peak inward current and current at the end
of the depolarizing pulse; absolute ICa in the t-tubular and surface
membranes was calculated from measurements of ICa and membrane
capacitance in intact and detubulated myocytes with correction for
incomplete detubulation as described previously (Bryant et al., 2015).
ICa was normalized to cell capacitance (pF; an index of membrane
area) to calculate ICa density (pA pF
−1). ICa density in the t-tubule
membrane was calculated from the loss of membrane current and
capacitance following DT; ICa density in the surface membrane was
calculated from currentsmeasured inDTmyocytes with correction for
incomplete detubulation as described previously (Bryant et al., 2015).
DT efficiency was not significantly different between cell types.
2.8 Measurement of SR Ca2+ release
Intracellular Ca2+ and membrane potential were recorded
simultaneously along single t-tubules as described previously (Bryant
et al., 2015). Briefly, myocytes were loaded with the Ca2+ indicator
Fluo-4/AM (5 𝜇mol l−1 for 25 mins; Thermo Fisher Scientific) and the
voltage sensitive dye di-4-AN(F)EPPTEA (0.5–1 𝜇g ml−1 for 15 min;
kindly supplied by Dr Leslie Loew; Yan et al., 2012). Cells were imaged
using a Zeiss LSM 880 (see above) with the confocal pinhole set to 1
Airy unit. Line-scan images along a selected t-tubule were recorded at
wavelengths between 518 and 560 nm for Ca2+, and 590 and 700 nm
for voltage, at a rate of 0.51 ms/line, with an excitation wavelength
of 514 nm. A negative deflection in di-4-AN(F)EPPTEA fluorescence
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was used to determine the time of the AP upstroke, and the latency
from the AP upstroke to the initial (>5 SD above average pre-stimulus
value) andmaximum rate of rise of Ca2+ was determined at each point
along the Fluo-4 line-scan image. The SD of latencies for each cell was
used as a measure of the heterogeneity of release. Whole-cell Ca2+
transients were obtained using line-scans along the long axis of cells
loaded with Fluo-4/AM only. Cells were field-stimulated at 0.2 Hz at
1.5 × threshold using parallel Pt electrodes.
2.9 Solutions
The standard superfusate for electrophysiology and imaging
experiments contained (in mM): 133 NaCl, 5 KCl, 1 MgSO4, 1
CaCl2, 1 Na2HPO4, 10 D-glucose, 10 HEPES, pH 7.4 (NaOH). During
electrophysiological recordings, KCl was replaced with CsCl to inhibit
K+ currents and the pipette solution contained (in mM): 110 CsCl,
20 TEACl, 0.5 MgCl2, 5 MgATP, 5 BAPTA, 10 HEPES, 0.4 GTP-Tris,
pH 7.2 (CsOH). For some experiments, cells were incubated in C3SD
peptide (Pepceuticals Limited, Enderby, UK, 1 𝜇M in 0.1 mM Ca2+) for
1 h at room temperature before use. C3SD was designed to mimic the
‘scaffolding domain’ of Cav-3 and thus to interfere with Cav-3 binding
to its endogenous partners and, as used in the present study, has pre-
viously been shown to inhibit Cav-3-dependent signalling in cardiac
myocytes (Bryant et al., 2018b). All experiments were performed at
room temperature.
2.10 Data presentation
Data are expressed as mean ± SD (of N animals for in vivo data
and of n cells from N animals (n/N) for cellular measurements). Data
normality was assessed using the Shapiro–Wilk test and subsequent
testing was performed using Student's t test or the Mann–Whitney
U test, one-way ANOVA, or the Kruskal–Wallis test, as appropriate.
ICa density–voltage relationship curves were analysed using repeated
measures (RM)ANOVAwith voltage and intervention as factors. Single
myocyte properties including those elicited by a step depolarization
to a single voltage were analysed with two-way ANOVA; post hoc
tests used the Bonferroni correction. The errors in derived variables
(specifically ICa density at the t-tubule and surface membranes), and
the subsequent statistical analysis (unpaired Student's t test), were
calculated using propagation of errors from the source measurements
(Bryant et al., 2015). The limit of statistical confidence was taken
as P < 0.05, and is denoted by * between treatments (e.g. sham vs.
TAC) for a given phenotype and by † between phenotypes (WT vs.
Cav-3OE).
3 RESULTS
3.1 The effect of TAC on cardiac structure and
function
Cardiac structure and function were assessed in vivo using
echocardiography; exemplar records from Cav-3 OE mice are shown
in Figure 1a; WT data have been shown previously (see Methods).
There was no significant difference between sham WT and Cav-3
OE mice for diastolic or systolic left ventricular volume (Figure 1b,c),
stroke volume or ejection fraction (Figure 1d,e), cardiac output (WT:
19.3 ± 4.2 ml min−1, N = 7; Cav-3 OE: 19.5 ± 2.8 ml min−1, N = 6;
P = 0.92; not shown) or left ventricular mass (WT: 150.3 ± 24.8 mg,
N = 7; Cav-3 OE: 141.3 ± 21.2 mg, N = 6; P = 0.50; not shown).
Following TAC, diastolic and systolic left ventricular volume increased,
and ejection fraction decreased, in both WT and Cav-3 OE mice
(Figure 1b,c,e), while stroke volume (Figure 1d) and thus cardiac
output (WT: 16.3 ± 6.1 ml min−1, N = 7, P = 0.30; Cav-3 OE:
11.5 ± 3.3 ml min−1, N = 6, P < 0.01) decreased significantly in
Cav-3 OE, but not WT mice. However, none of the measurements of
cardiac function were significantly different between WT and Cav-3
OE mice following TAC. Thus, it appears that Cav-3 OE has little
effect on in vivo cardiac function either in sham animals or following
TAC. However, although TAC increased left ventricular mass in both
types of mouse (to 339.6 ± 33.9 mg in WT, N = 7, P < 0.001; and
to 271.6 ± 24.7 mg in Cav-3 OE, N = 6, P < 0.001), left ventricular
mass was significantly smaller (P < 0.01) in Cav-3 OE than in WT
mice following TAC. Heart ratewas not significantly different between
groups (WT: sham446.9±7.3 bpm,N=7; TAC444.7±20.0 bpm,N=7,
P = 0.92; Cav-3 OE: sham 447 ± 27 bpm, N = 6; TAC 453 ± 54 bpm,
N= 6, P= 0.81).
Consistent with the changes observed in vivo, following TAC both
WT and Cav-3 OE mice showed a significant increase in wet heart
weight (WT: sham 210 ± 34 mg, N = 7, TAC 401 ± 77 mg, N = 8,
P < 0.001; Cav-3 OE: sham 227 ± 50 mg, N = 6, TAC 362 ± 35 mg,
N = 6, P < 0.001) and wet lung weight (WT: sham 146 ± 22 mg, N = 7,
TAC345±127mg,N=8,P<0.01; Cav-3OE: sham173±19mg,N=6,
TAC427±134mg,N=6,P<0.001), but no change inbodyweight (WT:
sham 28.5 ± 1.5 g, N = 7, TAC 28.3 ± 2.6 g, N = 8, P = 0.86; Cav-3 OE:
sham27.4±1.9 g,N=6;TAC26.6±4.6 g,N=6,P=0.68) or tibia length
(WT: sham 20.4 ± 0.6 mm, N = 7; TAC 19.8 ± 0.7 mm, N = 8, P = 0.10;
Cav-3 OE: sham 19.8 ± 0.9 mm, N = 6; TAC 19.6 ± 0.9 mm, N = 6,
P= 0.62). Thus, in bothWT andCav-3OEmice, TAC resulted in cardiac
hypertrophy, indicated by a significant increase in heart weight:tibia
length ratio (HW:TL; Figure 1f), and pulmonary congestion, a symptom
of congestive heart failure, indicated by a significant increase in lung
weight:tibia length ratio (LW:TL; Figure 1g); however, HW:TL following
TACwas significantly smaller in Cav-3 OE than inWTmice (Figure 1f).
These data suggest, therefore, that Cav-3 OE per se has little effect on
cardiac structure or function, but reduces the hypertrophy observed
following TAC. The magnitude of these changes was similar to that
reported previously in Cav-3 OE mice following TAC (Horikawa et al.,
2011, and see below).
3.2 The effect of TAC on cell morphology
Figure 2a shows exemplar confocal images of isolated Cav-3 OE myo-
cytes stained with di-8-ANEPPS, showing an increase in cell width,
suggesting cellular hypertrophy, and disruption of t-tubule structure
following TAC. Mean data show that in both WT and Cav-3 OE
myocytes, TAC increased cell length (WT: sham 166.1 ± 16.7 𝜇m,
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F IGURE 1 In vivo cardiac function andmorphology. (a) Exemplar left ventricularM-mode echocardiograms fromCav-3OEmice that had
undergone either a sham (left panel) or TAC (right panel) operation. Horizontal scale bar: 100ms; vertical scale bar: 4mm. (b–e)Measurements of
left ventricular function obtained by echocardiography from sham and TACWT (left) and Cav-3OE (right) mice. (b) Diastolic volume (𝜇l). (c)
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length ratio (LW:TL, mg/mm).N= 6 sham and 6 TACCav-3OEmice, and 7 sham and 7 TACWTmice. ***P< 0.001 between treatments for a given
phenotype (WT or Cav-3OE); †P< 0.05 between phenotypes for a given treatment (sham or TAC). TheWT data have been published previously
(Bryant et al., 2018a)
n/N = 41/10, TAC 192.0 ± 57.9 𝜇m, n/N = 21/5, P < 0.01; Cav-3 OE:
sham 149.3 ± 16.1 𝜇m, n/N = 19/5, TAC 178.3 ± 15.6 𝜇m, n/N = 22/5,
P < 0.001) and width (WT: sham 35.2 ± 5.3 𝜇m, n/N = 41/10, TAC
43.1 ± 3.9 𝜇m, n/N = 21/5, P < 0.001; Cav-3 OE: sham 36.7 ± 4.5 𝜇m,
n/N = 19/5, TAC 40.5 ± 5.0 𝜇m, n/N = 22/5, P < 0.05), and thus
calculated cell volume (Figure 2b). AlthoughCav-3OE had no effect on
cell volume in the absence of TAC, it was significantly smaller in Cav-3
OE than in WT myocytes following TAC (Figure 2b). Cell capacitance
(a function of membrane area) also increased significantly in both WT
and Cav-3 OE myocytes (Figure 2c), consistent with the development
of cellular hypertrophy in response to pressure overload.
Analysis of t-tubule structure using 2D FFT showed a significant
decrease in t-tubule regularity in both WT and Cav-3 OE myocytes
following TAC (P1/P0, Figure 2d). Since P1/P0 depends, inter alia, on
t-tubule density and orientation, further detailed analysis in 3D was
performed, which showed that this reduction in regularity was due, at
least in part, to a significant decrease in t-tubule density (Figure 2e)
and changes in tubule orientation, with a decrease in the fraction
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(n/N= 22/5) Cav-3OEmyocytes (right) comparedwithWT
sham (n/N= 41/10) and TAC (n/N= 21/5) myocytes (left). (d–f)
Analysis of t-tubule organization from di-8-ANEPPS-labelled
sham (n/N= 23/5) and TAC (n/N= 27/5) Cav-3OEmyocytes
(right) andWT sham (n/N= 40/8) and TAC (n/N= 21/5)
myocytes (left). (d) T-tubule power (P1/P0). (e,f) T-tubule density
(𝜇m 𝜇m−3; e) and T-tubule orientation (degrees from transverse
plane; f) inWT and Cav-3OEmyocytes. ***P< 0.001 between
treatments for a given phenotype (WT or Cav-3OE); †P< 0.05
between phenotypes for a given treatment (sham or TAC). The
WT data have been published previously (Bryant et al., 2018a)
of transverse (0–15◦) tubules (Figure 2f). However, the changes in
t-tubule structure were not significantly different between WT and
Cav-3OEmyocytes.
To ensure that Cav-3 expression was increased in OE mice, we
used western blotting. Figure 3a shows exemplar blots (left) and
correspondingmean densitometric analysis (right) showing that Cav-3
expression was increased ∼2-fold in OE compared to WT myocytes.
Cav-3 expression was not significantly altered following TAC in Cav-3
OEmyocytes, so that its expression level remained higher than in sham
and TACWTmyocytes. Since t-tubule structure was altered following
TAC in Cav-3 OE myocytes, we also investigated the expression of
JPH-2, which has been implicated in t-tubule and dyad formation.
Figure 3b shows exemplar blots (left) and corresponding mean
densitometric analysis (right) showing that JPH-2was not significantly
altered by Cav-3 OE but decreased following TAC in both WT and
Cav-3OEmyocytes.
In summary, Cav-3 OE appears to have little effect on cardiac and
cell morphology, and in vivo cardiac function, and the response to TAC
was qualitatively similar in WT and Cav-3 OE mice; however, both
heart weight and cell volume were significantly smaller in Cav-3 OE
mice than inWT, following TAC.
3.3 ICa distribution and regulation
To determine the distribution of ICa between the surface and t-tubular
membranes, ICa was measured in intact and DT myocytes. Figure 4
shows exemplar records of ICa recorded at 0mV from intact (Figure 4a,
top) andDT (Figure4b, top)myocytes isolated fromshamandTACCav-
3 OE hearts, with the corresponding mean current density–voltage
relationships shown below. Absolute ICa and ICa density were not
significantly different in WT and Cav-3 OE myocytes (Figure 4c,d).
However, the increase in cell capacitance caused by TAC in WT mice
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F IGURE 3 Effect of Cav-3OE and TAC on Cav-3 and JPH-2 protein expression. (a) Left panel, exemplar western blots of Cav-3 (18 kDa) and
GAPDH (37 kDa) in isolatedmyocyte lysates from threeWT sham (lanes 1), three Cav-3OE sham (lanes 2) and three Cav-3OE TAC (lanes 3) mice;
Right panel, densitometry analysis of Cav-3 western blots (N= 5 animals in each group in duplicate), comparedwith previously published data
(Bryant et al., 2018a) showing the effect of TAC on Cav-3 expression inWTmice (left two bars). (b) Left panel, exemplar western blots of JPH-2
(95 kDa) and GAPDH (37 kDa); right panel, densitometry analysis of JPH-2western blots (N= 5 animals in each group in duplicate), compared
with previously published data (Bryant et al., 2018a) showing the effect of TAC on JPH-2 expression inWTmice (left two bars). The blots in the left
panels are from the same gels which were stripped and re-probed for the different proteins andwere therefore obtained sequentially (see
Methods). Data in each group (WT or Cav-3OE) in the right panels are expressed as a percentage of themean of theWT data in that group.
**P< 0.01, between treatments for a given phenotype (WT or Cav-3OE); ††P< 0.01, †††P< 0.001 between phenotypes
(Figure 2c) occurred with little change in absolute ICa (Figure 4c), so
that ICa density decreased (Figure 4d); in contrast, in Cav-3 OE myo-
cytes, the TAC-induced increase in cell capacitance (Figure 2c) was
accompanied by an increase in absolute ICa amplitude (Figure 4c) so
that ICa density wasmaintained following TAC (Figure 4d).
Detubulation decreased ICa density in both sham (P < 0.001) and
TAC (P < 0.001) Cav-3 OE myocytes (cf. Figs 4a,b). However, there
was no significant difference in absolute ICa amplitude at the surface
membrane of sham and TAC Cav-3 OE myocytes (Figure 4C), so
that the increase in cell size (and thus capacitance) following TAC
resulted in a significant decrease in ICa density at the cell surface
(Figure 4d); this contrasts with the small increase in absolute ICa at
the surface membrane of WT myocytes following TAC, so that ICa
density at the surface membrane is unaltered following TAC in these
cells (Figure 4c,d). The lack of change of ICa density in intact Cav-3 OE
myocytes following TAC, despite a decrease at the surface membrane,
suggests that ICa density at the t-tubule membrane is increased.
Calculation of t-tubular ICa showed that absolute ICa is significantly
increased so that ICa density is maintained in the t-tubules of Cav-
3 OE myocytes following TAC (Figure 4c,d), in contrast to the lack
of change of absolute ICa and thus decrease in t-tubular ICa density
observed inWTmyocytes followingTAC (Figure4c,d). Thus, ICa density
at the cell surface decreases and t-tubular ICa density is preserved in
Cav-3 OE mice following TAC, whereas WT mice show no change at
the cell surface and a decrease in t-tubular ICa density in response to
TAC.
We have previously shown that incubating cells with C3SD, which
mimics the scaffolding domain of Cav-3 and has no effect on cell
capacitance (Bryant et al., 2014), decreases ICa density in intact WT
control myocytes (Bryant et al., 2018a; Kong et al., 2017), and that this
effect is lost following Cav-3 KO and in TAC-induced HF (Bryant et al.,
2018a). To investigate whether changes in this regulatory pathway
might underlie the different ICa distributions observed following TAC
in OE mice, we determined the response to C3SD in myocytes from
sham and TAC Cav-3 OE mice. Figure 4e,g show that in sham Cav-3
OE myocytes ICa density was increased by pre-treatment with C3SD,
as reported previously in myocytes from unoperated Cav-3 OE mice
(Kong et al., 2017) but in contrast to the decrease of ICa density
observed in sham WT myocytes in response to C3SD (Bryant et al.,
2018a; Figure4g).However, C3SDhadnoeffect on ICa density inCav-3
OEmyocytes following TAC (Figure 4f,h); this loss of response to C3SD
following TAC is similar to that reported in WT myocytes following
TAC (Bryant et al., 2018a; Figure 4h). This suggests that this regulatory
pathway is lost in both cell types and is not, therefore, responsible for
the different distribution of ICa density observed in OE and WT myo-
cytes following TAC.
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F IGURE 4 Surface and t-tubular ICa. (a) Top panel, exemplar
records of ICa from intact sham (black) and TAC (grey) Cav-3
OEmyocytes. Bottom panel, correspondingmean ICa
density–voltage relationships from sham (n/N= 19/5) and TAC
(n/N= 22/5) Cav-3OEmyocytes. Two-way repeatedmeasures
ANOVA:mV P< 0.001, TAC P= 0.4, interaction P< 0.9. (b) Top
panel, exemplar records of ICa from detubulated (DT) sham
(black) and TAC (grey) Cav-3OEmyocytes. Bottom panel:
correspondingmean ICa density–voltage relationships fromDT
sham (n/N= 19/5) and TAC (n/N= 21/5) Cav-3OEmyocytes.
Two-way repeatedmeasures ANOVA:mV P< 0.001, TAC
P< 0.001, interaction P< 0.001. (c,d) Absolute ICa (c) and ICa
density (d) at 0mV in intact Cav-3OEmyocytes, and at the cell
surface and t-tubules (obtained as described inMethods),
comparedwith previously published data (Bryant et al., 2018a)
fromWTmice. **P< 0.01, ***P< 0.001 between treatments for
a given phenotype (WT or Cav-3OE); †P< 0.05, ††P< 0.01,
†††P< 0.001 between phenotypes for a given treatment (sham
or TAC). (e) Mean ICa density–voltage relationships from sham
untreated (n/N= 19/5) and C3SD treated (n/N= 12/3) Cav-3
OEmyocytes. Two-way repeatedmeasures ANOVA:mV
P< 0.001, C3SD P= 0.014, interaction P< 0.001). (f) Mean ICa
density–voltage relationships from TAC untreated
(n/N= 22/5) and C3SD treated (n/N= 17/5) Cav-3OE
myocytes. Two-way repeatedmeasures ANOVA:mV P< 0.001,
C3SD P= 0.13, interaction P= 0.4. (g)Mean ICa density at 0mV
in sham untreated and C3SD treated Cav-3OEmyocytes,
comparedwith previously published data (Bryant et al., 2018a;
seeMethods) from sham untreated (n/N= 16/5) and C3SD
treated (n/N= 17/5)WTmyocytes. Two-way ANOVA: OE
P< 0.001, C3SD P= 0.4, interaction P< 0.001. (h)Mean ICa
density at 0mV in TAC untreated and C3SD treated Cav-3OE
myocytes, comparedwith previously published data (Bryant
et al., 2018a; seeMethods) from TAC untreated (n/N= 19/5)
and C3SD treated (n/N= 15/5)WTmyocytes. Two-way
ANOVA: OE P< 0.001, C3SD P= 0.14, interaction P= 0.84.
*P< 0.05, **P< 0.01 between treatments for a given
phenotype (WT or Cav-3OE); †††P< 0.001 between
phenotypes for a given treatment
3.4 Ca2+ release following TAC
To determine whether the preservation of t-tubular ICa in Cav-3 OE
myocytes helps to maintain Ca2+ release, we investigated the latency
and heterogeneity of Ca2+ release along a single t-tubule from the
time of membrane depolarization (Figure 5a), which showed that
Cav-3 OE had no significant effect on latency, nor did it affect the
increase in latency of both the initial andmaximum rate of rise of Ca2+
observed following TAC (Figure 5b, top), suggesting that TAC-induced
impairment of local Ca2+ release is unaffected by Cav-3 OE. However,
Cav-3 OE caused a significant decrease in the heterogeneity of
Ca2+ release compared to WT myocytes, and although heterogeneity
increased following TAC in both cell types, it remained smaller in Cav-
3 OE myocytes (Figure 5b, bottom) suggesting more uniform Ca2+
release along the t-tubules following Cav-3 OE. However, TAC had
little effect on theearly (release) phaseof thewhole cellCa2+ transient,
which was not significantly different in WT and Cav-3 OE myocytes
and showed no change in either time to peak or amplitude (Figure 5c).
3.5 Comparisonwith HF inWTmyocytes
Figure 6 shows the ratio of the data from Cav-3 OE mice to those
from WT mice, in sham (left) and in mice in HF following TAC (right).
These data show thatCav-3OEhad little effect onmeasurements from
sham hearts and myocytes, consistent with previous work showing
little effect of Cav-3 OE on cardiac morphology or function in the
absence of TAC (Horikawa et al., 2011; Kong et al., 2017; Markandeya
et al., 2015). However, following TAC, HW:TL and cell volume were
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F IGURE 5 Local Ca2+ release and systolic Ca2+ transient. (a) Line-scan images of the rising phase of the Ca2+ transient and (below) the
associated average t-tubular di-4-AN(F)EPPTEA signal in representative sham (top) and TAC (bottom) Cav-3OEmyocytes. Horizontal scale bar:
10ms; vertical scale bar: 5 𝜇m. The time of the AP upstroke, initial rise of Ca2+ andmaximum rate of rise of Ca2+ have beenmarked in yellow, red
and blue, respectively. (b)Mean latency and heterogeneity of SR Ca2+ release in sham (n/N= 28/5) and TAC (n/N= 18/4) Cav-3OEmyocytes
comparedwithWT sham (n/N= 43/12) and TAC (n/N= 12/3) myocytes. (c)Whole cell Ca2+ transient amplitude (F/F0) and time to peak (ms)
measured fromCa2+ transients of sham (n/N= 25/5) and TAC (n/N= 22/4) Cav-3OEmyocytes comparedwithWT sham (n/N= 53/13) and TAC
(n/N= 14/3) myocytes. *P< 0.05, **P< 0.01, ***P< 0.001 between treatments for a given phenotype (WT or Cav-3OE); †P< 0.05, ††P< 0.01
between phenotypes for a given treatment (sham or TAC). TheWT data have been published previously (Bryant et al., 2018a)
significantly smaller in OE than in WT, consistent with previous work
(Horikawa et al., 2011; Markandeya et al., 2015). In addition, ICa
amplitude and density were greater in intact OE than in WT myo-
cytes, as a result of a small decrease at the cell surface but a large
increase at the t-tubules. Thus, the decrease in t-tubular ICa normally
observed following TAC (Bryant et al., 2018a) is prevented by Cav-3
overexpression, and although Cav-3 OE exerts an anti-hypertrophic
effect and increases ICa, these effects only become apparent following
TAC.
4 DISCUSSION
The present data show that TAC caused qualitatively similar changes
in Cav-3 OE mice to those reported previously in WT mice (Bryant
et al., 2018a): cardiac hypertrophy and failure, with disrupted cell
structure and function. However, the cardiac and cellular hypertrophy
associated with TAC were smaller in OE animals and t-tubular ICa
density wasmaintained, although ICa density at the surfacemembrane
decreased; this contrasts with the decrease in t-tubular ICa density
with no change at the cell surface observed in WT myocytes. Thus
Cav-3 OE appears to confer limited but specific protection against the
effects of TAC.
4.1 Cardiac structure and function
Echocardiography showed that Cav-3 OE had little effect on cardiac
structure or function in sham animals (Figure 1). Following TAC,
diastolic and systolic left ventricular volume and left ventricular mass
increased, and post mortem measurements also showed an increase
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F IGURE 6 Comparison ofWT andOE data. Plots showing the ratio of data fromCav-3OEmice to those fromWTmice,± 95% confidence
intervals, in sham (left) and in HF following TAC (right). TheWT data have been published previously (Bryant et al., 2018a). The x-axis shows the
change relative toWT: an increase in Cav-3OEmice compared toWT results in a value>1, while a decrease results in a value<1. The coloured
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different in Cav-3OE andWTmice (statistical analysis performed using original data). LVVD, left ventricular volume at diastole, 𝜇l; LVVS, left
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latency from action potential depolarization, ms; Ca2+ heterogeneity, calcium transient heterogeneity during upstroke, ms; Ca2+ amplitude,
calcium transient amplitude, F/F0; Ca
2+ time to peak, ms
in HW:TL and LW:TL in Cav-3 OE mice. However, although cardiac
function was not significantly different in WT and Cav-3 OE mice
following TAC, the hypertrophic response to TAC was smaller in Cav-
3 OE than in WT mice. These changes are similar to those reported
previously following 4 weeks TAC in Cav-3 OE mice (Horikawa et al.,
2011) and suggest that Cav-3 OE has maintained anti-hypertrophic
effects following TAC, consistent with the idea that Cav-3 inhibits
the hypertrophic p42/44mitogen-activated protein kinase (Woodman
et al., 2002) and calmodulin-dependent calcineurin/nuclear factor of
activated T cells (Markandeya et al., 2015) pathways.
Following TAC, cardiac function was not significantly different, and
there were similar decreases in ejection fraction, in WT and Cav-
3 OE mice. However, stroke volume and cardiac output decreased
significantly inCav-3OEbutnot inWTmice followingTAC.This implies
that an increase in heart size in WT (cf. the larger scatter in Figure 1b)
compared toCav-3OEmicehelped tomaintain stroke volumeand thus
cardiac output despite similar decreases in ejection fraction. Thus, the
anti-hypertrophic effect ofCav-3OEmay impair the ability of theheart
tomaintain cardiac output.
Previous work has shown that 4 weeks’ TAC caused only a small
(not significant) decrease in cardiac function in Cav-3 OE mice, but a
significant decrease in WT mice (Horikawa et al., 2011; Markandeya
et al., 2015). The contrast with the current work may be due to the
longer (8 weeks) exposure to TAC in the present study. Taken together
these data suggest that, while the anti-hypertrophic effect of Cav-3 is
maintained, the deleterious effect on cardiac function, while slowed
in onset, can still occur in Cav-3 OE mice following TAC. However,
the observation that Cav-3 OE has little effect on either the size or
the function of the heart in the absence of TAC (Figure 6; Horikawa
et al., 2011; Markandeya et al., 2015) suggests that Cav-3 expression
is normally sufficient to inhibit hypertrophy and enable normal ECC.
4.2 Cell structure
In the absence of TAC, Cav-3 OE had little effect on cell size or
structure, as reported previously (Kong et al., 2017), but cells were
larger and t-tubule structure was disrupted following TAC, as in WT
myocytes (Bryant et al., 2018a). However, the increase in cell volume
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following TAC was significantly smaller in OE than in WT myocytes,
providing a mechanism for the reduced hypertrophy observed in the
whole heart and consistent with the suggestion that caveolin inhibits
hypertrophic pathways (Galbiati et al., 1998; Markandeya et al., 2015;
Woodman et al., 2002). Knockout and loss-of-function mutations
of Cav-3 are associated with hypertrophic cardiomyopathy, further
supporting a role for Cav-3 as an inhibitor of cardiac hypertrophic
signalling pathways (Hayashi et al., 2004;Woodman et al., 2002).
4.3 Cell function
Cav-3 OE had little effect on the function of myocytes from sham
hearts. However, the distribution of ICa was markedly different in OE
and WT myocytes following TAC. TAC-induced heart failure in WT
mice is associated with a decrease in t-tubular ICa density due to
cellular hypertrophywith no change in absolute current, andno change
in ICa density at the cell surface (Bryant et al., 2018a). In contrast, inOE
myocytes, there was no change in t-tubular ICa density following TAC,
because absolute current increased proportionally with membrane
area, but ICa density at the cell surface decreased, since absolute ICa
was unchangeddespite cellular hypertrophy. Thus, followingTAC,Cav-
3OEmaintains ICa density at the t-tubularmembranebutnot at the cell
surface.
Previous work has shown that chronically decreasing Cav-3
expression, via either KO or TAC, leads to decreased t-tubular ICa
density as a result of an increase in membrane area (Bryant et al.,
2018a),whereas acute disruptionofCav-3 activity usingC3SDpeptide
decreases ICa with no changeof capacitance (Bryant et al., 2018a;Kong
et al., 2017). However, in agreement with previous work (Kong et al.,
2017), the present data show that C3SD increases ICa in OE myocytes
although, as inWTmyocytes, this regulation was lost following TAC.
These data suggest that Cav-3 alters ICa density by (at least) two
mechanisms. The first is by altering cell growth. It has previously been
suggested that Cav-3 is anti-hypertrophic (Woodman et al., 2002),
consistent with the observations in vivo, and in KO and WT TAC myo-
cytes. Previous work has shown that hypertrophic pathways can be
activated by Ca2+ entry via LTCCs (Gao et al., 2012), although LTCCs
localized to caveolae do not appear to contribute to hypertrophic
signalling in mouse ventricular myocytes (Correll et al., 2017); thus
Cav-3 may inhibit hypertrophic signalling by altering the distribution
of LTCCs, and thus ICa. The present study suggests that Cav-3 OE does
not augment the anti-hypertrophic effect of basal Cav-3 levels in sham
myocytes, since cell volume and capacitance in the absence of TAC are
similar in WT and OE myocytes. However, Cav-3 OE does appear to
be anti-hypertrophic following TAC, when OE myocytes are smaller
than those from WT. Thus, it appears that Cav-3 levels are normally
sufficient to inhibit hypertrophy, and only become insufficient to do so
following TAC, either because Cav-3 levels decrease and/or because
of stimulation of hypertrophic pathways. This anti-hypertrophic effect
of Cav-3 following TAC will help to maintain ICa density. However, the
observation that absolute t-tubular ICa increases suggests additional
effects of Cav-3 OE, in particular modulation of acute signalling
pathways. Previous work suggests that Cav-3 helps localize ICa to
the t-tubules, and C3SD decreases t-tubular ICa in WT myocytes,
although this effect is lost following TAC (Bryant et al., 2018a). It
has been suggested that Cav-3-dependent stimulation of ICa is due
to co-localization of LTCCs with components of the protein kinase A
pathway (Bryant et al., 2014). However, recent work has shown LTCC
clustering leading to co-operative gating (Ghosh et al., 2018); if Cav-3
plays a role in this process, loss of Cav-3 activity would be expected to
decrease ICa. The present study shows that C3SD increases ICa in sham
Cav-3 OE myocytes, suggesting that the levels of Cav-3 expression
achieved inOEmyocytesmay inhibit theseCav-3 dependent pathways.
Such inhibition could occur as the result of autoinhibition or because
there is abnormally located Cav-3 in OE myocytes which competes
with normally localized proteins. Reducing Cav-3 expression, activity
or regulation, via TAC or C3SD, may relieve this inhibitory effect to
produce the increases in ICa observed in these conditions; the loss of
effect of C3SD on ICa following TAC is also indicative of such loss of
Cav-3 dependent regulation.
In contrast to t-tubular ICa, ICa density at the cell surface decreased
following TAC in Cav-3OEmice, due to cellular hypertrophy with little
change in absolute ICa. Thus, following TAC, in OE myocytes t-tubular
ICa appears to be maintained at the expense of ICa at the surface
membrane, whereas in WT myocytes t-tubular ICa density decreases
with no change at the cell surface. This suggests that changes in Cav-
3 expression occur predominantly at the t-tubules, where it competes
with that at the surface membrane to bind the proteins which localize
ICa.
Regardless of the mechanism underlying the maintenance of t-
tubular ICa, the latency and heterogeneity of local Ca
2+ release at the
t-tubule still increased following TAC which, with the disruption of t-
tubule morphology also observed following TAC, would be expected
to desynchronize Ca2+ release and thus impair contraction. However,
the whole cell Ca2+ transient showed little change, suggesting that it
is dominated by other factors and is not responsible for the impaired
cardiac performance observed following TAC. However, the Ca2+
transient was monitored at a low stimulation frequency (0.2 Hz)
compared with the mouse's normal heart rate, to enable comparison
with ICa, which was recorded at this frequency to allow recovery
from inactivation between voltage clamp pulses. It remains possible,
therefore, that changes in local Ca2+ release may decrease Ca2+
transient amplitude, and thus impair cardiac performance, at physio-
logical frequencies. However, the impairment occurred in the presence
of increased heart size, so that reduced stroke volume and ejection
fraction do not necessarily imply reduced contractility because myo-
cyte contractionwill have to overcome the higherwall tension thatwill
result from the increase in heart size (law of Laplace).
The lackof effect ofCav-3OEon the latencyofCa2+ releasedespite
the recovery of t-tubular ICa suggests that the decrease in ICa is not the
primary cause of disruption of Ca2+ release following TAC. This may
be because of redundancy in the Ca2+-induced Ca2+ release process
(Cannell, Berlin, & Lederer, 1987) in mice, and/or because the LTCCs,
and thus ICa, which are regulated by Cav-3 are predominantly extra-
dyadic (Glukhov et al., 2015; Sanchez-Alonso et al., 2016), which could
also explain why similar decreases in ICa amplitude produced by Ca
2+
channel blockers, which will affect all Ca2+ channels, inhibit release
(Bryant et al., 2015). The TAC-induced disruption of Ca2+ release may,
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therefore, be due predominantly to disruption of the dyad (Louch
et al., 2013), consistent with the observed decrease in JPH-2 and with
recent work showing dispersion of RyR clusters in rat myocytes in
HF (Kolstad et al., 2018), so that RyR dispersion and loss of t-tubular
ICa may have summative effects that impair Ca
2+ release along t-
tubules. Interestingly, however,Cav-3OEdecreased theheterogeneity
of Ca2+ release in both sham and TACmyocytes, suggesting that Cav-3
may increase the uniformity of t-tubular Ca2+ release by altering the
distribution of ICa or the response to ICa along the t-tubule.
5 SUMMARY
These data show that Cav-3 OE alone has little effect on the
structure or function of either the whole heart or ventricular myo-
cytes. However, following TAC, Cav-3 OE is anti-hypertrophic and
helps to maintain t-tubular ICa; this is not secondary to the smaller
increase in t-tubularmembrane area inOEmyocytes, because absolute
ICa increases. This attenuation of the TAC phenotype by Cav-3 OE is
consistent with previouswork suggesting that Cav-3 plays a role in the
local regulation of ICa and is anti-hypertrophic, but it remains unclear
whether these effects are direct or secondary.
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